Skip to main content
. 2014 May 28;20(20):6081–6091. doi: 10.3748/wjg.v20.i20.6081

Table 3.

Bevacizumab with chemotherapy as induction therapy before chemo-radiotherapy: Overview of the discussed studies

Ref. Phase n Treatment Stage Post-operative complications (n) pCR
Dipetrillo et al[26], 2012 II 25 Induction FOLFOX + BV followed by BV 5 mg/kg, 5-FU 200 mg/m2 daily, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr. II-III Infection (4) 20%
Delayed healing (3)
Leak/abscess (2)
Sterile fluid collection (2)
Ischemic colonic reservoir (1)
Fistula (1)
Nogué et al[27], 2011 II 47 Induction XELOX + BV followed by BV 5 mg/kg, CAPE 825 mg/m2 bid, RT 50.4 Gy in 28 fr. II-III Wound infection (10) 36%
Intra-abdominal infections (7)
Anastomotic leak (5)
Stoma complications (2)
Other (not specified) (10)
Vivaldi et al[28], 2013 II 15 Induction FOLFOXIRI + BV followed by BV 5 mg/kg, CAPE 825 mg/m2 bid or 5-FU 225 mg/m2 daily, RT 50.4 Gy in 28 fr. II-III Dehiscence of anastomosis (1) 38%

CT: Chemotherapy; CT-RT: Chemo-radiotherapy; BV: Bevacizumab; RT: Radiotherapy; 5-FU: 5-fluorouracil; CAPE: Capecitabine; fr.: Fractions; FOLFOX: 5-FU and oxaliplatin; XELOX: Capecitabine and oxaliplatin; pCR: Pathological complete response.